Safety and immunogenicity following 2 doses of BNT162b2 COVID-19 vaccine in an early phase oncology trial center population
2017 ◽
Vol 44
(2)
◽
pp. 121-127
◽
1970 ◽
Vol 24
(1)
◽
pp. 10-13
1960 ◽
Vol XXXIII
(III)
◽
pp. 457-472
◽
Keyword(s):